ArticleBiology direct2026
MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) remains challenging due to chemotherapy resistance and disease relapse. Investigating novel regulators of AML pathogenesis and drug sensitivity is crucial for improving outcomes. Myocyte enhancer factor 2 A (MEF2A) was selected for this study based on its potential role in oncogenic pathways and the unmet need to understand its impact on AML progression and doxorubicin (DOX) chemoresistance.
methodsBioinformatics analysis of the GSE245305 dataset was used to identify the differentially expressed genes between AML and normal samples. MEF2A and zDHHC palmitoyltransferase 20 (ZDHHC20) mRNA expression was validated using quantitative real-time PCR (qRT-PCR). Western blotting and immunohistochemistry (IHC) assays were performed to analyze protein expression. Functional assays were performed to analyze cell viability, proliferation, apoptosis, and glucose metabolism. Mechanistic studies involved dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to validate the association of MEF2A and ZDHHC20. A xenograft mouse model was used to assess the effect of MEF2A knockdown on tumor sensitivity to DOX.
resultsMEF2A exhibited upregulated expression in AML samples in comparison with healthy samples. Its knockdown suppressed proliferation, glycolysis (reducing glucose uptake, lactate production, and ATP levels), and tumor growth, while increasing apoptosis and DOX sensitivity in AML cells. Critically, MEF2A transcriptionally activated ZDHHC20 in HL-60 and KG-1 cells. ZDHHC20 overexpression reversed the antitumor effects of MEF2A silencing, promoting malignancy and DOX resistance. Mechanistically, MEF2A depletion inactivated the nuclear factor kappa B (NF-κB) pathway via ZDHHC20 downregulation. In vivo, MEF2A knockdown significantly enhanced the sensitivity of AML xenografts to DOX treatment.
conclusionMEF2A promoted AML progression and DOX resistance by transcriptionally upregulating ZDHHC20, thereby activating the NF-κB pathway. Targeting the MEF2A/ZDHHC20 axis represents a promising therapeutic strategy to overcome chemoresistance and improve clinical outcomes in AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.